Do dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer?
Both early/transient/proliferation response genes and continuous/late/estrogen-response genes are able to predict prognosis of primary breast tumours in a dynamic manner. Temporal expression of therapy-response genes is clearly an important factor in characterising the response to endocrine therapy in breast tumours which has significant implications for the timing of biopsies in neoadjuvant biomarker studies.
These results suggest that hPDL cells may play a role in the production of cytokines in response to mechanical stress in vivo.